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Objective: This review aimed to summarize the application of single-cell transcriptome sequencing
technology in liver diseases.
Background: The increasing application of single-cell ribonucleic acid (RNA) sequencing (scRNA-seq)
in life science and biomedical research has greatly improved our understanding of cellular heterogeneity
in immunology, oncology, and developmental biology. scRNA-seq has proven to be a powerful tool
for identifying and classifying cell subsets, characterizing rare or small cell subsets and tracking cell
differentiation along the dynamic cell stages. Globally, liver disease has high rates of morbidity and mortality,
and its exact pathological mechanism remains unclear, current treatment options are limited to clearance of
the underlying cause or liver transplantation, which cannot overwhelm and cure liver diseases. scRNA-seq
provides many novel insights for healthy and diseased livers.
Methods: In this review, we searched for related articles in the PubMed database and summarized the
advances of scRNA-seq in revealing the molecular mechanisms of liver development, regeneration, and
disease. We also discussed the challenges and future application potential of scRNA-seq, which is expected
to enhance the ability to explore the field of liver research and accelerate the clinical application of liver
precision medicine.
Conclusions: With the continuous improvement of scRNA-seq technology, scRNA-seq is expected to
unlock new avenues for liver biology exploration, liver disease diagnosis, and personalized treatment, which
will pave the way for breakthrough innovation in personalized medicine.
Keywords: Single cell RNA sequence (scRNA-seq); cellular heterogeneity; liver disease; precision medicine
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Introduction
As the largest solid organ in the body, the liver contains
heterogeneous cell types with unique spatial, molecular, and
functional characteristics (1). Most hepatocytes form liver
parenchymal cells (2), while non-parenchymal cells (NPCs)
include liver sinusoidal endothelial cells (LSECs), Kupffer
cells (KCs), and hepatic stellate cells (HSCs), bile duct cells,
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and other immune cell populations mainly composed of
natural killer T cells (3,4). Globally, liver disease has high
rates of morbidity and mortality (5,6). Studies have shown
that liver disease persists through the coordination of liver
parenchymal cells and NPCs (7-10). The pathological
mechanisms of liver disease may involve a large and complex
network of cellular and molecular mechanisms, but there is
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a lack of detailed analysis defining the cellular and molecular
mechanisms that drive these diseases, and current treatment
options are limited to clearance of the underlying cause or
liver transplantation. Therefore, uncovering the molecular
mechanism of hepatocyte heterogeneity and studying new
effective therapeutic strategies remains challenging.
Cells are the basic structural and functional units of
organisms, and the potential heterogeneity within cells is a basic
characteristic of cellular homeostasis and development (11).
Traditional gene expression analysis techniques are
limited to the cell population level and can only obtain
the average genetic information reflecting the dominant
cell subpopulation, while the role of the secondary cell
subpopulation is often ignored (12). Thus, the biological
behavior of individual cells may also be ignored, resulting in
the loss of cell heterogeneity information.
The emerging scRNA-seq technique possesses advantages
including the ability to analyze transcriptome heterogeneity
that is masked in bulk RNA, as well as the ability to identify
rare cell types and new cell states. This has profound
implications for understanding the physiological functions
and biological processes associated with human disease
(13,14). In the era of immunotherapy and precision medicine,
higher resolution sequencing data is needed to characterize
heterogeneous tissues and complex diseases, such as chronic
liver disease. Recently, studies using scRNA-seq have revealed
the emergence of diverse liver parenchymal and NPCs
from their endodermal and mesodermal ancestors during
embryonic development, found the zone-specific alterations
of LSECs in Cirrhosis (15,16), identified subsets of HSCs
and provided a transcriptional roadmap for the activation
of HSCs during liver fibrosis (17,18). ScRNA-seq not only
explored the heterogeneity of liver-resident immune cells but
also revealed the presence of triggering receptor expressed
on myeloid cells 2(TREM2)+ macrophages, ACKR1+ and
PLVAP+ endothelial cells expanding in cirrhosis in fibrotic
livers (19-21).
Through scRNA-seq, cell transcription maps can be
mapped with unprecedented resolution, and cellular
heterogeneity in liver development and disease can be
described (22). This will greatly promote the understanding
of human liver health and disease.
In this paper, we discussed the scRNA-seq technique,
data visualization analysis methods and how it has
changed our understanding of liver biology and disease
pathogenesis, and unlocked new strategies for finding
effective novel treatments for patients with liver diseases.
We also predicted the technical improvements and clinical
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applications of scRNA-seq in the future as it is still limited
by cost, technology, complexity of data processing, etc.
We present the following article in accordance with the
Narrative Review reporting checklist (available at https://
dx.doi.org/10.21037/atm-21-4824).
Methods
In the current narrative review, we conducted a literature
search for papers published up to June 2021 on scRNA-seq
and liver in the PubMed database, all of the included studies
were written in English. The vast majority of researched
literature was focused on the application of single-cell RNA
sequencing technology in liver.
Single-cell transcriptome sequencing technology
Workflow of single-cell transcriptome sequencing
With the innovation of sequencing technology, numerous
scRNA-seq technologies have been developed, which have
different methods of cell capture and amplification, messenger
ribonucleic acid (mRNA) transcript length, number of
captured target cells, and reading depth of each cell (23). Each
approach has its own unique advantages and disadvantages,
but overall, all of the scRNA-seq techniques developed to date
follow a common workflow: single-cell isolation and library
generation, sequencing, and visual analysis.
Single-cell isolation and library generation
Single-cell isolation is the limiting step of scRNA-seq, and
library preparation is also a key factor that improves the
throughput of high-throughput scRNA-seq research. In
2009, Tang et al. (24) detected and captured only six cells
through micromanipulation. In recent years, commercial
instruments developed by 10× Genomics can simultaneously
prepare approximately 48,000 single cells from eight different
samples (25). It is clear that scRNA-seq technology has been
rapidly developed. Once successfully captured, individual cells
are reverse transcribed into complementary deoxyribonucleic
acid (cDNA), which is then amplified by polymerase chain
reaction (PCR) or in vitro transcription (IVT) to generate
high-throughput sequencing libraries (26).
ScRNA-seq platform
Methods for isolating individual cells for RNA sequencing
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vary by the number of cells isolated (high or low
throughput) and the way in which cells are selected (biased
or unbiased) (27). The available platforms fall into two
categories according to the downstream methods: dropletbased [e.g., Drop-seq (28), inDrop (29), 10× Chromium
Genomics (25), and Seq-well (30)] and plate-based [e.g.,
STRT-seq (31), SmartSeq (32), SmartSeq2 (33), and
MARS-Seq (34)]. Droplet-based approaches are suitable
for generating large numbers of cells to identify subsets
of cells in a complex tissue or tumor sample such as the
liver. The three most widely used platforms are Dropseq, inDrop, and 10× Chromium Genomics, each of
which uses microfluidics. Individual cells are labeled with
individual magnetic beads with unique barcodes, and each
mRNA transcript is also associated with a unique molecular
identifier (UMI). Methods for generating a unit sequencing
database are based on the full-length and tag-based methods
(35,36). Compared with tag-based methods, the fulllength scRNA-seq method has incomparable advantages
in isomer use analysis, allele expression detection, as well
as RNA editing and identification due to its advantages in
transcription coverage (32). In addition, some scRNA-seq
techniques, such as SUPeR-seq (37) and MATQ-seq (38),
can simultaneously capture polyA+ and polyA-RNA, which
has profound implications for the sequencing of long noncoding RNAs (lncRNAs) and circular RNAs (circRNAs).
A few issues need to be considered in order to decide
which one suits any particular researcher’s needs best.
Plate-based and droplet platforms are suitable for normal
and small cells, while full-length methods can also be used
independently of all cell types or sizes, allowing analysis of
large and rod-shaped cells, such as adult cardiomyocytes (39).
Plate based protocols can provide experimental flexibility
for long-term stored cell samples. Researchers interested
in the details of each cell should choose highly sensitive
protocols, such as SMART-seq2, MARS-Seq, which are
more suitable for fewer cells (35,40,41). Droplet-based
techniques are often used as high-throughput studies, which
are suitable for generating large numbers of cells to identify
subpopulations of cells in complex tissues or tumour
samples like the liver. Full-length methods are superior
for isoform analysis, allele detection and RNA editing
identification (32).
Currently, scRNA-seq includes a variety of technologies,
and the selection of sequencing platforms should be guided
by biological questions, with the appropriate technology or
combination of technologies selected based on the context
of the study design and the desired endpoint.
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scRNA-seq data processing and visual analysis
Due to the relative lack of starting materials, improved
resolution, loss of cDNA synthesis, and error of cDNA
amplification, the scRNA-seq data set has considerable
technical noise and serious quantitative error (42).
Therefore, after the completion of sequencing, quality
control of the data should be carried out to assess the
gene expression level of qualified cells (43) and the gene
expression level of qualified cells can be evaluated by
FASTQC, Qualimap2, RSeQ and CQoRT (43-46), tools
such as HTSeq and WemIQ (47,48) can align reads to a
reference genome and calculate the relative quantization
of mRNA molecules for each gene in each cell, reads can
be assigned to reference annotated genes via STAR (49)
and feature Counts (50). Subsequently, public platforms
(such as Cell Ranger of 10× Genomics) should be used to
generate the feature barcode matrix and create the original
gene expression count matrix (43). Due to factors such as
reverse transcription efficiency, primer capture efficiency,
and errors related to UMIs, the proportion of RNA
captured by each cell may be different (51,52), and the
difference in the total amount of UMIs or reads in each cell
may be caused by technical factors rather than biological
variation. Therefore, normalization is critical to reveal the
true biological heterogeneity of the dataset, and the use of
specialized normalization methods, such as SCnorm and
sctransform, can unlock heterogeneity in the dataset (52).
Finally, numerous toolkits are used for visualization and
data analysis. Table 1 summaries some visualization analysis
toolkits that are representative in the scRNA-seq field (53-62).
Biology of the liver at the single-cell level
Hepatocyte mapping and liver partitioning
MacParland et al. (63) mapped the transcription profiles
of 8,444 human hepatocytes and NPCs at singlecell resolution and identified 20 hepatocyte subsets.
Subsequently, Ramachandran et al. (19) used the healthy
cell bank to generate a single cell atlas of human liver
NPCs and identified 21 cell subsets. Zhao et al. (21) given
a global glimpse on B cell and plasma cell subsets and
revealed the heterogeneity and functional diversity of
liver-resident immune cells in human. Aizarani et al. (64)
revealed a human liver cell atlas and analyzed the
heterogeneity of LSECs, KCs, and hepatocyte subtypes,
as well as the transcriptomic range of hepatocytes. These
results suggest that the heterogeneity of the epithelial cell
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Table 1 scRNA-seq visualisation analysis toolkits
Toolkits

Synopsis

Reference

Seurat

Quality control, cell clustering, analysis of differentially
expressed genes, identification of marker genes

Butler et al. Nat Biotechnol 2018 (53)
Satija et al. Nat Biotechnol 2015 (54)

Monocle
Velocyto

Pseudo-time analysis

Trapnell et al. Nat Biotechnol 2014 (55)
La Manno et al. Nature 2018 (56)

StemID

Lineage tracing

Grün et al. Cell Stem Cell 2016 (57)

SCODE
SCENIC

Analysis single-cell gene regulatory network

Matsumoto et al. Bioinformatics 2017 (58)
Van de Sande et al. Nat Protoc 2020 (59)

CellPhoneDB
NicheNet

Infer cell-cell communication from combined
expression of multi-subunit ligand-receptor complexes

Efremova et al. Nat Protoc 2020 (60)
Browaeys et al. Nat Methods 2020 (61)

SingleR

Automatic cluster annotation

Aran et al. Nat Immunol 2019 (62)

scRNA, single cell RNA sequence.

adhesion molecule (EPCAM)+ cell population and the new
EPCAM+ trophoblast cell-surface antigen 2 (TROP2)
population may be involved in homeostasis transition,
liver regeneration, chronic disease occurrence, and tumor
formation. Mapping the human liver in health and disease
with single-cell resolution will facilitate the construction of
human liver models, which is essential for understanding
the pathogenesis and treatment of liver disease.
Liver zonation refers to the differential expression of
liver genes along the lobe axis of hepatic lobules, which
is a prominent aspect of hepatocyte heterogeneity (65).
Studies based on normal human livers have shown that
the liver is divided into nine levels that have different
gene expression profiles, and hepatocytes are divided into
pericentral hepatocytes, periportal hepatocytes, and middle
hepatocytes (63,66,67). Pathway analysis has demonstrated
that periportal hepatocytes enrich oxidation and fatty
acid metabolism genes, while middle hepatocytes enrich
cytochrome P450 xenometabolic genes (64). Dobie et al. (68)
found through scRNA-seq of healthy and fibrotic mouse
hepatocytes that HSCs could be divided into two regions:
portal vena-associated hepatic stellate cells (PaHSCs) and
central vena-associated hepatic stellate cells (CaHSCs).
Halpern et al. (67) found that 50% of hepatocyte genes were
significantly zoned as detected by scRNA-seq combined
with single-molecule fluorescence in situ hybridization,
confirming that middle hepatocytes play a key role in the
expression of bile acid synthesis genes, and revealing the
gene expression profile of hepatocytes in adult mouse liver
lobules by zonation and spatial division. This study provides
information for the study of liver cell zonation in the human
liver. Subsequently, Aizarani et al. (64) performed pseudo-
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spatial trajectory analysis using scRNA-seq to sequence the
arrangement of human hepatocytes in the hepatic lobules,
and the results showed similar genetic banding patterns to
those observed in mice. Hepatocyte localization is critical to
the response of hepatocytes to injury, so further studies on
the relationship between hepatocyte zonation and hepatocyte
heterogeneity in liver pathology are needed to promote the
understanding of the pathogenesis of liver disease.
Liver development and regeneration
Camp et al. (69) used scRNA-seq to explore the effect of a
three-dimensional (3D) culture system on cell characteristics
and differentiation, and found that vascular endothelial
growth factor (VEGF) was derived from mesenchymal
and hepatic lineages within the human liver bud. VEGF
enhances endothelial cell proliferation network formation
and hepatoblast differentiation, revealing interlineage
communication in liver development. Su et al. (70)
identified cells with liver and mesenchymal markers coexpressed by Dlk1 and Vimentin, which indicated that
epithelial-mesenchymal transition (EMT) or mesenchymalepithelial transition (MET) may be involved in the
differentiation of fetal liver stem/progenitor cells (LSPCs)
into hepatocytes, Notch signaling in liver development
has also been found to be associated with bile duct cell
differentiation, further promoting the understanding of
the mechanisms of hepatocyte development and LSPC
differentiation.
The liver has significant regeneration and repair ability (71).
In mouse models of liver injury, the proliferation subsets
of hepatocytes were randomly distributed in the periportal
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area, pericentral area, and hepatic lobule (72-74). Aizarani
et al. (64) detected some alpha-fetoprotein (AFP) + positive
human hepatocytes. MacParland et al. (63) also found the
heterogeneity of human hepatocytes and distinguished
AFP+ and AFP− hepatocytes, and observed that AFP+
hepatocytes were enriched in cell division and the
hepatocyte mitogen signaling pathway interleukin-6 (IL-6).
Both AFP+ and AFP− hepatocytes were distributed in the
hepatic lobule, suggesting that AFP+ and AFP− hepatocytes
may possess regenerative ability in liver. Another scRNA-seq
data based on human health and regenerative liver epithelia
also found a physiological bile acid-induced yes-associated
protein (YAP) transcription module, revealing that YAP
drives the dynamic heterogeneity of biliary epithelial cells
(BECs) and is critical to the response to regenerative duct
injury in hepatocytes (75). These studies provide favorable
evidence for the heterogeneity and molecular mechanisms
of liver cells during liver development, differentiation, and
damage repair, and will promote future research on liver
development and disease.
Liver immunity and inflammation
Hepatic immune cells have been shown to regulate key
pathological processes in liver diseases, including fibrosis
and cancerization (76). In non-alcoholic steatohepatitis
(NASH), persistent liver injury triggers recruitment and
reprogramming of various immune cells (77). Xiong
et al. conducted scRNA-seq on NPCs isolated from
the liver of healthy and diet-induced NASH mice and
found that NASH-associated macrophages (NAM)
were characterized by high expression of the Trem2
receptor, which was related to the severity of the disease
and strongly responded to pharmacological and dietary
interventions (20). MacParland et al. (63) revealed
the presence of two CD68 macrophage populations
that are associated with hepatic inflammation and
immunoregulatory phenotypes. Other scRNA-seq studies
have also defined CD163+MARCO+CD5L+TIMD4+
macrophage populations in human KCs, revealing
s u b p o p u l a t i o n s o f T R E M 2 + C D 9 + M N D A + s c a rassociated macrophages (SAMacs) located in the scar
region of fibrotic human liver, which can promote the
production and proliferation of HSCs collagen (19,63,64).
The ligand receptor interaction model with endothelial
cells and PDGFR collagen-producing cells revealed the
intrascar activity of TNFRSF12A, PDGFR, and NOTCH
fibrophilic pathways (19). In addition, CD8+T enriched
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population cells and cytotoxic T lymphocyte-associated 4
(CTLA4high) regulated T cells were also identified in human
hepatocellular carcinoma (HCC) T cell scRNA-seq, which
were associated with impaired antitumor immunity (78).
Specific macrophage subsets play a dominant role in
the development of chronic liver disease (79). The
characteristics of these macrophage subsets in humans will
create an important foundation for the study of the role of
macrophage subsets in liver disease.
Liver fibrosis is the result of chronic hepatitis, as well
as the basic event for the development of cirrhosis or
HCC (80). The main characteristic of chronic hepatitis
leading to liver fibrosis is the activation of HSCs and their
transformation into myofibroblasts (MFB) (81). ScRNAseq study confirmed and expanded the transcriptional
characteristics and spatial division of HSCs. During chronic
liver disease, HSCs not only produce collagen, but also
secrete cytokines. These secreted cytokines are increased
in NASH mice, mainly acting on endothelial cells and
immune cells, highlighting the important role of HSCs
in coordinating the response to liver injury (17,20,68).
Dobie et al. (68) also identified that CaHSCs were the main
pathogenic collagenic cells in the mouse model of fibrosis,
and in the genetic characteristics of CaHSCs, blocking
lysophosphatidic acid receptor 1 (LPAR1) could inhibit liver
fibrosis in the rodent NASH model. Therefore, LPAR1 may
be a potential therapeutic target for liver fibrosis. Krenkel
et al. (17) confirmed through fibrotic mouse liver that MFBs
are marked by the expression of activated tumor-related
protein S100 calcium binding protein A6 (S100a6) and can
be further divided into subgroups with immunomodulatory
or portal vena fibroblast-like characteristics, showing
heterogeneity and functional diversity. In conclusion,
scRNA-seq research on liver inflammation has deepened
the understanding of the precise cellular and molecular
mechanisms of liver fibrosis, and provided favorable support
for the rational design and development of highly targeted
anti-fiber therapies for patients with chronic liver disease.
Liver tumors and the tumor microenvironment
The liver is a common site of primary and metastatic
tumors. Genetic or genomic variation can lead to different
genetic and phenotypic characteristics of cells in tumor
tissues, resulting in high heterogeneity of tumor tissues (82).
Such high heterogeneity may be related to tumor genesis
and metastasis (83,84), and is currently a major obstacle
to treatment (85). ScRNA-seq has revealed the single-cell

Ann Transl Med 2021;9(20):1598 | https://dx.doi.org/10.21037/atm-21-4824

He et al. scRNA-seq in liver diseases

Page 6 of 11

transcriptome characteristics of HCC and identified two
HCC cell populations characterized by EPCAM differential
expression and CD24+/CD44+. CD24+/CD44+-enriched
cells specifically express Krt20, S100a6, Vim, and Ctse,
among which S100a6 may promote the development of
HCC (86). Ma et al. (87) found heterogeneity in HCC cells
and the tumor microenvironment (TME), and the degree of
heterogeneity was negatively correlated with the prognosis
of patients, revealing that the expression of VEGF was
correlated with tumor diversity and T cell dysfunction. This
provides a theoretical basis for the combination therapy of
immunosuppressive agents and anti-VEGF. Zheng et al. (78)
performed scRNA-seq on single T cells from HCC
patients, and found that Ccr8 and Layn are marker genes
for HCC-related regulatory T cells, suggesting that Layn

has an inhibitory function on T cells and may be a negative
regulator involved in tumor killing, and thus, could be a
potential therapeutic target for HCC.
The in-depth study of scRNA-seq on liver tumors and
the tumor microenvironment is helpful to understand liver
tumors and the tumor microenvironment, as well as to
discover effective biomarkers, new tumor immunotherapies,
and drug therapy targets, which is of great significance for
the diagnosis and personalized treatment of liver tumors.
Table 2 summarizes the application of scRNA-seq in the liver.
Current challenges and future prospects
In recent years, transcriptomics has made great strides
from the initial study of cell populations to the analysis of

Table 2 Brief overview of scRNA-seq in the liver
Species

Year

Model

Finding

Reference

Human

2018

Healthy development

Present a comprehensive view of the human
MacParland et al. Communications (63)
liver, provide a map of the human hepatic immune
microenvironment

Human

2019

Healthy development and
liver cirrhosis

Identify a scar-associated subpopulation of
macrophages, define two endothelial cells that
expand in cirrhosis, reveal intra-scar activity of
several pro-fibrogenic pathways

Ramachandran et al. Nature (19)

Human

2020

Healthy development

Present comprehensively the landscape of liverresident immune cells

Zhao et al. Cell Discov (21)

Human

2019

Healthy development

Construct a human liver cell atlas, reveal
Aizarani et al. Nature (64)
previously unknown subtypes of endothelial cells,
KCs, and hepatocytes

Mouse

2019

Healthy development and
liver fibrotic

Reveal spatial zonation of HSCs, identify LPAR1
as a therapeutic target on collagen-producing
CaHSCs

Mouse

2017

Healthy development

Find that around 50% of liver genes are
Halpern et al. Nature (67)
significantly zonated and uncover abundant nonmonotonic profiles that peak at the mid-lobule
layers

Human

2017

Healthy development

Reveal interlineage communication regulating
organoid development and Vegf crosstalk
potentiates endothelial Network formation and
hepatoblast differentiation

Camp et al. Nature (69)

Mouse

2017

Healthy development

Identify LSPCs in developing mouse livers

Su et al. BMC Genomics (70)

Mouse

2019

Healthy development and
NASH

Uncover the emergence of NASH-associated
macrophages, which are marked by high
expression of Trem2

Xiong et al. Molecular Cell (20)

Dobie et al. Cell Rep (68)

Table 2 (continued)
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Table 2 (continued)
Species

Year

Model

Finding

Reference

Human

2017

Hepatocellular carcinoma

Identify 11 T cell subsets and delineate their
developmental trajectory

Zheng et al. Cell (78)

Mouse

2019

Liver fibrosis

Demonstrate the heterogeneity of activated MFB Krenkel et al. Cells (17)
in vivo and highlight the differences of in vivo and
in vitro activated MFB

Human

2019

Hepatocellular carcinoma

Reveal two distinct major cell populations
according to EPCAM expression, identify a cell
subpopulation within the EPCAM+ cells

Ho et al. Cancer Lett (86)

Human

2019

Hepatocellular carcinoma

Find varying degrees of heterogeneity in
malignant cells within and between tumors and
diverse landscapes of tumor microenvironment

Ma et al. Cancer Cell (87)

scRNA, single cell RNA sequence; KCs, Kupffer cells; HSCs, hepatic stellate cells; LPAR1, lysophosphatidic acid receptor 1; CaHSCs,
vena-associated hepatic stellate cells; VEGF, vascular endothelial growth factor; LSPCs, liver stem/progenitor cells, NASH, non-alcoholic
steatohepatitis; Trem2, triggering receptor expressed on myeloid cells 2; MFB, myofibroblasts; EPCAM, epithelial cell adhesion molecule.

individual cells. ScRNA-seq has played an important role
in identifying new cell subsets, elucidating the trajectory of
differentiation, and describing intercellular interactions in a
variety of developmental, regenerative, and disease settings.
An important aspect of tissue cell heterogeneity is the
spatial environment of cells (88). The preparation of liver
single-cell suspension leads to the loss of spatial information
of liver cells. Meanwhile, single-cell sequencing technology
also has problems, such as cumbersome operation, RNA
loss in the sequencing process, high detection cost and
complex data processing.
In order to ensure that scRNA-seq provides a better
service for liver clinical research, we can supplement
transcriptome analysis with other “omics” methods to
address the above limitations, such as integrating DNA
methylation, RNA, protein, and epigenetic modification
information to further understand the association between
cell phenotypes and genotypes (89). The latest spatial
transcriptome technology can trace the gene expression
information of cells to the original spatial location in
tissues (90). In addition, mass cytometry can conduct an
overall process of analysis and imaging mass cytometry
(IMC) can acquire spatial information (91). Nowadays,
most scRNA-seq studies currently tend to detect freshly
isolated cells, we expect that they will tend to explore
cryopreservation and immobilization of tissue samples
in the future, which will open up clinical research of this
technique from a specialized research area to a routine
research tool for basic scientists and clinicians. For example,
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clinical samples can be routinely evaluated on a regular
basis, which will provide clinical data to inform the best
options for diagnosis, disease progression and treatment. A
further experimental improvement in the field of scRNAseq is to increase the sensitivity and accuracy of the assay,
thereby reducing the volume of reactions to reduce costs.
Alongside technological improvements, computational
methods have to be developed in the future, researchers
will be able to process and visualise data in a web interface
conveniently and quickly. As these technologies develop
further, they will reveal multi-dimensional details of the
liver microenvironment in physiological and disease states.
This will help to promote a new era of precision medicine
in hepatology by decoding the molecular mechanisms that
regulate human liver disease at single-cell resolution.
With the continuous improvement of scRNA-seq
technology, the reduction of sequencing costs, and the
progress of precision medicine, scRNA-seq is expected
to unlock new avenues for liver biology exploration, liver
disease diagnosis, and personalized treatment.
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